Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene in Postmenopausal Osteoporosis (MORE)
NCT00670319Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 1994
- Primary completion
- Sep 1999
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of raloxifene in postmenopausal osteoporosis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Rate of new vertebral fractures at 72 months, Bone Mineral Density at 72 months and 1 more. Started Nov 1994; status: completed.
02
Drugs
raloxifene
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00670319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00670319.